Scherrer JF, et al. - Using the Veterans Health Administration (VHA) medical record data, researchers investigated the impact of race on the already reported association of metformin use with a lower risk of dementia than sulfonylureas. They extracted data for 73,761 African American and white patients aged ≥50 years who used the VHA. During fiscal years 2000 and 2001, patients were free of dementia and diabetes medications, then metformin or sulfonylurea monotherapy was started. Substantially lower risk of dementia was reported in younger African American patients in relation to metformin vs sulfonylurea initiation.